Something new under the skin

  title={Something new under the skin},
  author={M. Eisenstein},
  journal={Nature Biotechnology},
One-size-fits-all intravenous delivery of biologics may be giving way to alternate delivery routes that enable safer and more efficient drug administration. Michael Eisenstein reports. 

Tables and Topics from this paper

Subcutaneous Drug Delivery: A Route to Increased Safety, Patient Satisfaction, and Reduced Costs
Therapeutics are being formulated with an enzyme, recombinant human hyaluronidase, to enhance the dispersion and absorption of SC administered therapeutics by transiently depolymerizing hyaluranan, a major component of the interstitial matrix. Expand
Polymeric microneedles for transdermal protein delivery☆
This review surveys the current design and use of polymeric MNs for transdermal protein delivery and discusses the clinical potential and future translation of MNs. Expand
Microneedle-Assisted Transdermal Delivery of Etanercept for Rheumatoid Arthritis Treatment
A hyaluronic acid crosslinked microneedle system was constructed as the transdermal alternative to deliver etanercept and possessed sufficient mechanical strength, good biocompatibility, little influence on the bioactivity of EN, and high anti-inflammatory efficacy. Expand
In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability
This work proposes in silico tools that provide rapid assessment of atypical behavior of mAbs (high viscosity, chemical degradation, and fast plasma clearance), which are simply predicted from sequence and/or structure-derived parameters, which should aid in more rapid screening and selection of mAb candidates during early discovery. Expand
Silk Fibroin Microneedle Patches for the Sustained Release of Levonorgestrel
Modifications in the formulation of the silk protein and drug loading enabled the tuning of drug loading and release rates from the microneedle patches over time, suggesting that long-acting contraception patches are feasible. Expand
Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry.
The strategies of therapeutic antibodies in-depth characterization by mass spectrometry (MS) and analytical comparison of biosimilar to originator mAbs, with the cases of trastuzumab and cetuximab are introduced. Expand
Therapeutic potential of conopeptides.
Recent efforts at chemically re-engineering conopeptides to improve their biopharmaceutical properties promise to accelerate the translation of these fascinating marine peptides to the clinic. Expand
Evaluating the administration costs of biologic drugs: development of a cost algorithm
This paper evaluates variations in the administration costs of biologic drugs and develops a regression-based algorithm with which manufacturers could possibly predict, during process development, how their manufacturing and formulation choices may impact on the healthcare delivery costs of their products. Expand
Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity
It is found that an IgG1 mAb (mAb-J) undergoes RSA primarily through electrostatic interactions and forms a monomer-dimer-tetramer equilibrium, the first direct experimental mapping of the interface formed between the Fab and Fc domains of an antibody at high protein concentrations. Expand
The effects of flow on therapeutic protein aggregation
To date, over 70 monoclonal antibody (mAb) biopharmaceuticals have been approved, allowing effective treatment of serious diseases such as cancer. In addition to improving human health, theseExpand


In vitro transdermal delivery of therapeutic antibodies using maltose microneedles.
M maltose microneedles provide a means for the transdermal delivery of macromolecules and it is demonstrated that IgG follows microchannels for transport across the skin. Expand
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study
It is confirmed that low-dose subcutaneous alemtuzumab is effective in poor prognosis CLL, and has a particularly favourable toxicity profile. Expand
Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer.
Drug penetration and ocular biodistribution patterns of ESBA105 applied as eye drops appear highly attractive for clinical use to treat TNF-alpha dependant diseases of the eye. Expand
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Subcutaneous alemTuzumab appears as effective and safe as intravenous alemtuzumAB in fludarabine-refractory CLL and overcomes the adverse prognostic impact of VH mutation status, TP53 mutation, and genomic aberrations. Expand